Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Jul;62(1):127–132. doi: 10.1038/bjc.1990.243

The long-term effects of MVPP chemotherapy for Hodgkin's disease on bone marrow function.

J A Radford 1, N G Testa 1, D Crowther 1
PMCID: PMC1971744  PMID: 2390472

Abstract

Using in vitro techniques, bone marrow (BM) function has been studied in 25 patients in complete remission and at least one year after the completion of MVPP chemotherapy for Hodgkin's disease. The numbers of granulocyte/macrophage (GM-CFC) and fibroblastoid (CFU-F) progenitors were significantly lower than controls and there was no evidence of any improvement with time (median months off treatment was 30 for GM-CFC and 34 for CFU-F). In long-term BM culture production of haemopoietic cells were strikingly lower in the post-MVPP group and the development of adherent stromal cell populations was also significantly less. In addition, the yield of GM-CFC in adherent layers after four weeks of culture was significantly lower than in controls. We conclude that following MVPP chemotherapy and in apparently disease free and haematologically normal individuals there is evidence of impaired BM function up to nine years after the completion of treatment. These abnormalities may be relevant to the known increased risk of acute non-lymphocytic leukaemias in this group of patients and are likely to render the BM less able to withstand subsequent insults such as further chemotherapy or infection. The eventual development of BM failure is also a possibility and long-term follow-up of these patients is essential.

Full text

PDF
127

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976 Aug;33(4):451–458. doi: 10.1111/j.1365-2141.1976.tb03563.x. [DOI] [PubMed] [Google Scholar]
  2. Boivin J. F., Hutchison G. B. Leukemia and other cancers after radiotherapy and chemotherapy for Hodgkin's disease. J Natl Cancer Inst. 1981 Oct;67(4):751–760. [PubMed] [Google Scholar]
  3. Bonadonna G., Monfardini S. Cardiac toxicity of daunorubicin. Lancet. 1969 Apr 19;1(7599):837–837. [PubMed] [Google Scholar]
  4. Bull J. M., DeVita V. T., Carbone P. P. In vitro granulocyte production in patients with Hodgkin's disease and lymphocytic, histiocytic, and mixed lymphomas. Blood. 1975 Jun;45(6):833–842. [PubMed] [Google Scholar]
  5. Coltman C. A., Jr, Dixon D. O. Second malignancies complicating Hodgkin's disease: a Southwest Oncology Group 10-year followup. Cancer Treat Rep. 1982 Apr;66(4):1023–1033. [PubMed] [Google Scholar]
  6. Coulombel L., Eaves A. C., Eaves C. J. Enzymatic treatment of long-term human marrow cultures reveals the preferential location of primitive hemopoietic progenitors in the adherent layer. Blood. 1983 Aug;62(2):291–297. [PubMed] [Google Scholar]
  7. Coutinho L. H., Testa N. G., Dexter T. M. The myelosuppressive effect of recombinant interferon gamma in short-term and long-term marrow cultures. Br J Haematol. 1986 Jul;63(3):517–524. doi: 10.1111/j.1365-2141.1986.tb07529.x. [DOI] [PubMed] [Google Scholar]
  8. DeVita V. T., Jr, Simon R. M., Hubbard S. M., Young R. C., Berard C. W., Moxley J. H., 3rd, Frei E., 3rd, Carbone P. P., Canellos G. P. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med. 1980 May;92(5):587–595. doi: 10.7326/0003-4819-92-5-587. [DOI] [PubMed] [Google Scholar]
  9. Glicksman A. S., Pajak T. F., Gottlieb A., Nissen N., Stutzman L., Cooper M. R. Second malignant neoplasms in patients successfully treated for Hodgkin's disease: a Cancer and Leukemia Group B study. Cancer Treat Rep. 1982 Apr;66(4):1035–1044. [PubMed] [Google Scholar]
  10. Hartmann O., Parmentier C., Lemerle J., Gout M., Schweisguth O. Sequential study of the bone marrow granulocytic progenitor cells (CFC *) in children treated by chemotherapy for non-hodgkin malignant lymphomas. Nouv Rev Fr Hematol. 1979;21(3):239–250. [PubMed] [Google Scholar]
  11. Haworth C., Morris-Jones P. H., Testa N. G. Long-term bone-marrow damage in children treated for ALL: evidence from in vitro colony assays (GM-CFC and CFUF). Br J Cancer. 1982 Dec;46(6):918–923. doi: 10.1038/bjc.1982.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Inoue S., Ravindranath Y., Lusher J. M., Ito T. Hematological parameters and marrow in vitro colony forming cells in acute lymphoblastic leukemia after cessation of treatment. Nihon Ketsueki Gakkai Zasshi. 1980 Feb;43(1):61–70. [PubMed] [Google Scholar]
  13. Mauch P., Botnick L. E., Hannon E. C., Obbagy J., Hellman S. Decline in bone marrow proliferative capacity as a function of age. Blood. 1982 Jul;60(1):245–252. [PubMed] [Google Scholar]
  14. Morley A., Blake J. An animal model of chronic aplastic marrow failure. I. Late marrow failure after busulfan. Blood. 1974 Jul;44(1):49–56. [PubMed] [Google Scholar]
  15. Morley A., Trainor K., Blake J. A primary stem cell lesion in experimental chronic hypoplastic marrow failure. Blood. 1975 May;45(5):681–688. [PubMed] [Google Scholar]
  16. Myers C. D., Katz F. E., Joshi G., Millar J. L. A cell line secreting stimulating factors for CFU-GEMM culture. Blood. 1984 Jul;64(1):152–155. [PubMed] [Google Scholar]
  17. Pedersen-Bjergaard J., Larsen S. O. Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. N Engl J Med. 1982 Oct 14;307(16):965–971. doi: 10.1056/NEJM198210143071601. [DOI] [PubMed] [Google Scholar]
  18. Schofield R., Dexter T. M., Lord B. I., Testa N. G. Comparison of haemopoiesis in young and old mice. Mech Ageing Dev. 1986 Mar;34(1):1–12. doi: 10.1016/0047-6374(86)90100-4. [DOI] [PubMed] [Google Scholar]
  19. Shalet S. M. Effects of cancer chemotherapy on gonadal function of patients. Cancer Treat Rev. 1980 Sep;7(3):141–152. doi: 10.1016/s0305-7372(80)80028-4. [DOI] [PubMed] [Google Scholar]
  20. Sostman H. D., Matthay R. A., Putman C. E. Cytotoxic drug-induced lung disease. Am J Med. 1977 Apr;62(4):608–615. doi: 10.1016/0002-9343(77)90424-7. [DOI] [PubMed] [Google Scholar]
  21. Sutcliffe S. B., Wrigley P. F., Peto J., Lister T. A., Stansfeld A. G., Whitehouse J. M., Crowther D., Malpas J. S. MVPP chemotherapy regimen for advanced Hodgkin's disease. Br Med J. 1978 Mar 18;1(6114):679–683. doi: 10.1136/bmj.1.6114.679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Testa N. G., Hendry J. H., Molineux G. Long-term bone marrow damage in experimental systems and in patients after radiation or chemotherapy. Anticancer Res. 1985 Jan-Feb;5(1):101–110. [PubMed] [Google Scholar]
  23. Tester W. J., Kinsella T. J., Waller B., Makuch R. W., Kelley P. A., Glatstein E., DeVita V. T. Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. J Clin Oncol. 1984 Jul;2(7):762–769. doi: 10.1200/JCO.1984.2.7.762. [DOI] [PubMed] [Google Scholar]
  24. Wagstaff J., Gregory W. M., Swindell R., Crowther D., Lister T. A. Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centres. Br J Cancer. 1988 Oct;58(4):487–492. doi: 10.1038/bjc.1988.246. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES